Literature DB >> 19696217

Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Fellype C Barreto1, Daniela V Barreto, Sophie Liabeuf, Natalie Meert, Griet Glorieux, Mohammed Temmar, Gabriel Choukroun, Raymond Vanholder, Ziad A Massy.   

Abstract

BACKGROUND AND OBJECTIVES: As a major component of uremic syndrome, cardiovascular disease is largely responsible for the high mortality observed in chronic kidney disease (CKD). Preclinical studies have evidenced an association between serum levels of indoxyl sulfate (IS, a protein-bound uremic toxin) and vascular alterations. The aim of this study is to investigate the association between serum IS, vascular calcification, vascular stiffness, and mortality in a cohort of CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One-hundred and thirty-nine patients (mean +/- SD age: 67 +/- 12; 60% male) at different stages of CKD (8% at stage 2, 26.5% at stage 3, 26.5% at stage 4, 7% at stage 5, and 32% at stage 5D) were enrolled.
RESULTS: Baseline IS levels presented an inverse relationship with renal function and a direct relationship with aortic calcification and pulse wave velocity. During the follow-up period (605 +/- 217 d), 25 patients died, mostly because of cardiovascular events (n = 18). In crude survival analyses, the highest IS tertile was a powerful predictor of overall and cardiovascular mortality (P = 0.001 and 0.012, respectively). The predictive power of IS for death was maintained after adjustment for age, gender, diabetes, albumin, hemoglobin, phosphate, and aortic calcification.
CONCLUSIONS: The study presented here indicates that IS may have a significant role in the vascular disease and higher mortality observed in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696217      PMCID: PMC2758258          DOI: 10.2215/CJN.03980609

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

1.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; G M London
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

Review 2.  A bench to bedside view of uremic toxins.

Authors:  Raymond Vanholder; Ulrich Baurmeister; Philippe Brunet; Gerald Cohen; Griet Glorieux; Joachim Jankowski
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

3.  AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis.

Authors:  Haruhiko Ueda; Nobuhisa Shibahara; Shizuko Takagi; Toru Inoue; Yoji Katsuoka
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

4.  Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake.

Authors:  Masaru Motojima; Atsuko Hosokawa; Hideyuki Yamato; Takamura Muraki; Toshimasa Yoshioka
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness.

Authors:  Mahmoud Zureik; Mohammed Temmar; Chris Adamopoulos; Jeanne-Marie Bureau; Dominique Courbon; Frédérique Thomas; Kathryn Bean; Pierre-Jean Touboul; Pierre Ducimetière; Athanase Benetos
Journal:  J Hypertens       Date:  2002-01       Impact factor: 4.844

Review 6.  Cardiovascular disease in chronic renal insufficiency.

Authors:  A Levin; R N Foley
Journal:  Am J Kidney Dis       Date:  2000-12       Impact factor: 8.860

7.  Vitamin D affects survival independently of vascular calcification in chronic kidney disease.

Authors:  Daniela Veit Barreto; Fellype Carvalho Barreto; Sophie Liabeuf; Mohammed Temmar; Francis Boitte; Gabriel Choukroun; Albert Fournier; Ziad A Massy
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 8.237

8.  Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.

Authors:  Hideki Fujii; Fuyuhiko Nishijima; Sumie Goto; Mikio Sugano; Hideyuki Yamato; Riko Kitazawa; Sohei Kitazawa; Masafumi Fukagawa
Journal:  Nephrol Dial Transplant       Date:  2009-02-02       Impact factor: 5.992

9.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

Authors:  Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

10.  Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification.

Authors:  Julien Maizel; Isabelle Six; Michel Slama; Christophe Tribouilloy; Henry Sevestre; Sabrina Poirot; Philippe Giummelly; Jeffrey Atkinson; Gabriel Choukroun; Michel Andrejak; Said Kamel; Jean Claude Mazière; Ziad A Massy
Journal:  Circulation       Date:  2008-12-31       Impact factor: 29.690

View more
  323 in total

1.  Selectively increasing the clearance of protein-bound uremic solutes.

Authors:  Tammy L Sirich; Frank J-G Luo; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer
Journal:  Nephrol Dial Transplant       Date:  2012-01-09       Impact factor: 5.992

2.  Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction.

Authors:  Hideki Fujii; Yuriko Yonekura; Yusuke Yamashita; Keiji Kono; Kentaro Nakai; Shunsuke Goto; Mikio Sugano; Sumie Goto; Ayako Fujieda; Yoshiharu Ito; Shinichi Nishi
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

Review 3.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

4.  Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.

Authors:  Mina Yu; Young Ju Kim; Duk-Hee Kang
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

5.  The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis.

Authors:  Xinyu Ge; Liang Zheng; Rulin Zhuang; Ping Yu; Zhican Xu; Guanya Liu; Xiaoling Xi; Xiaohui Zhou; Huimin Fan
Journal:  Adv Nutr       Date:  2020-01-01       Impact factor: 8.701

Review 6.  Analytical approaches to metabolomics and applications to systems biology.

Authors:  Jeffrey H Wang; Jaeman Byun; Subramaniam Pennathur
Journal:  Semin Nephrol       Date:  2010-09       Impact factor: 5.299

7.  The relationship between serum indoxyl sulfate and the renal function after catheter ablation of atrial fibrillation in patients with mild renal dysfunction.

Authors:  Hideki Koike; Toshisuke Morita; Junko Tatebe; Ippei Watanabe; Makiko Koike; Shintaro Yao; Masaya Shinohara; Hitomi Yuzawa; Takeya Suzuki; Tadashi Fujino; Takanori Ikeda
Journal:  Heart Vessels       Date:  2018-11-08       Impact factor: 2.037

Review 8.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

Review 9.  Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.

Authors:  Natalia Lucía Rukavina Mikusic; Nicolás Martín Kouyoumdzian; Marcelo Roberto Choi
Journal:  Pflugers Arch       Date:  2020-02-17       Impact factor: 3.657

10.  The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.

Authors:  Jennifer C Schroeder; Brett C Dinatale; Iain A Murray; Colin A Flaveny; Qiang Liu; Elizabeth M Laurenzana; Jyh Ming Lin; Stephen C Strom; Curtis J Omiecinski; Shantu Amin; Gary H Perdew
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.